Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the predicted strain coverage in Europe.
Methods: We assessed invasive MenB strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain.
Findings: 1052 strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB strains contained at least one gene encoding a major antigen in the vaccine. MATS predicted that 78% of all MenB strains would be killed by postvaccination sera (95% CI 63-90, range of point estimates 73-87% in individual country panels). Half of all strains and 64% of covered strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries.
Interpretation: MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future.
Funding: Novartis Vaccines and Diagnostics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1473-3099(13)70006-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
Vaccine
August 2025
Vaccine Evaluation Unit, UK Health Security Agency, Manchester Royal Infirmary, Manchester, UK.; Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Manchester, UK.
Background/objectives: Cases of Invasive Meningococcal Disease (IMD) dropped sharply due to non-pharmaceutical interventions during the Covid-19 pandemic, raising the possibility of a disease rebound due to an immunity gap. This has been investigated via a seroprevalence study of individuals less than 25 years old, by measuring meningococcal serogroup B (MenB) serum bactericidal antibody (SBA) titres in sera collected during 2019, 2020 and 2021. SBA titres in vaccine-eligible populations since the introduction of 4CMenB were also evaluated via comparison with data obtained before vaccine introduction.
View Article and Find Full Text PDFCharacteristics of Neisseria meningitidis isolated from patients with urogenital infection in a region of China.
Ann Clin Microbiol Antimicrob
July 2025
Department of Clinical Laboratory Medicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai, 200443, China.
Background: Neisseria meningitidis (Nm), traditionally recognized as a nasopharyngeal commensal causing invasive meningococcal disease (IMD), has recently emerged as an etiological agent of urethritis worldwide, with sporadic urogenital cases in China raising epidemiological concerns.
Methods: Three urogenital Nm isolates were characterized to investigate their evolutionary features and transmission patterns. Through comprehensive laboratory characterization encompassing culture identification (Gram staining, oxidase testing, MALDI-TOF MS), antimicrobial susceptibility profiling, whole-genome sequencing, and functional colonization assays on urethral epithelial cells under nitrite-supplemented microaerobic conditions, three multidrug-resistant Nm isolates were identified.
Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains.
Diagn Microbiol Infect Dis
October 2025
Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL, UK. Electronic address:
Background: The serum bactericidal antibody using human complement (hSBA) assay, the accepted surrogate measure of meningococcal vaccine efficacy, is limited by human sera and complement requirements. Pfizer developed and validated the flow-cytometry-based Meningococcal Antigen Surface Expression (MEASURE) assay to quantify surface-expressed factor H binding protein (fHbp) levels on intact meningococci. Surface expression of fHbp is correlated with hSBA assay killing by MenB-fHbp (Trumenba)-induced antibody, meaning the MEASURE assay can be used to predict meningococcal serogroup B (MenB) strain susceptibility to antibodies elicited by MenB-fHbp.
View Article and Find Full Text PDFRecent advances on the syntheses of oligosaccharides and the corresponding glycoconjugates towards development of vaccine candidates against invasive Neisseria meningitidis strains.
Carbohydr Res
September 2025
Department of Chemistry, Jadavpur University, Kolkata, 700 032, India; Department of Chemistry, Rani Rashmoni Green University, Hooghly, Tarakeswar, 712410, West Bengal, India. Electronic address:
NEISSERIA MENINGITIDIS: (Men) is one of the reasons of meningitis and sepsis worldwide. Mainly affected groups are children below five years and adolescents. Out of thirteen different Men-serogroups, disease causing invasive ones are the following six groups: A, B, C, W, X and Y.
View Article and Find Full Text PDFDeciphering the Code of Viral-Host Adaptation Through Maximum-Entropy Nucleotide Bias Models.
Mol Biol Evol
June 2025
CNRS UMR 8023, Laboratory of Physics of the Ecole Normale Supérieure and PSL Research, Sorbonne Université, Paris, France.
How viruses evolve largely depends on their hosts. To quantitatively characterize this dependence, we introduce Maximum Entropy Nucleotide Bias models (MENB) learned from single, di- and tri-nucleotide usage of viral sequences that infect a given host. We first use MENB to classify the viral family and the host of a virus from its genome, among four families of ssRNA viruses and three hosts.
View Article and Find Full Text PDF